brickellia paniculata/鎮痙剤

BACKGROUND Brickellia veronicifolia (Kunth) Gray (Asteraceae) (BV) is broadly commercialized for treating gastrointestinal diseases (stomach aches, biliary colics and dyspepsia), arthritis, diabetes and painful inflammatory complaints. OBJECTIVE In order to complete the preclinical pharmacological

Chemical fractionation of Brickellia paniculata methanolic extract by monitoring its inhibitory effect on K(+)-induced contraction in guinea-pig ileum in vitro led to the isolation of 5,4'-dihydroxy-6,7,8-trimethoxyflavone (xanthomicrol) and the labdane-diterpene 3 alpha-angeloyloxy-2

The present investigation describes the effect of the spasmolytic benzylbenzoates 1-9 from Brickellia veronicifolia on CaM using a functional in vitro enzymatic assay. Bovine brain PDE1 was used as a monitoring enzyme. The most active natural inhibitors of the system CaM-PDE1 were benzyl benzoates

Brickellia paniculata has been used as spasmolytic in Mexican traditional medicine. Xanthomicrol and 3alpha-angeloyloxy-2alpha-hydroxy-13,14Z-dehydrocativic acid (AAHDD) are two of the main leaf components with antispasmodic activity. However, their mechanism of action remains unknown. An in vitro

The composition of the spasmolytic essential oil of the medicinal species Brickellia veronicaefolia was established by NMR spectroscopy in addition to GC-MS analysis and HPLC studies. Seven major compounds, representing ca. 86% of the oil, were identified as benzyl 2,6-dimethoxybenzoate (1),